Search clinical trials for: Inhaled GSK573719/vilanterol

Total 1108 results

GlaxoSmithKline

Completed

Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment

Pulmonary Disease, Chronic Obstructive

Czechia, Hungary
GlaxoSmithKline

Completed

A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

Hungary, Slovakia
GlaxoSmithKline

Completed

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (DB2113361)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Ukraine, Estonia, Belgium, France, Sweden, Netherlands, Philippines, Denmark, Hungary, Norway, Slovakia
Queen's University
GlaxoSmithKline

Completed

Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD

COPD

Canada
GlaxoSmithKline

Completed

Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Ukraine, Germany, Peru, Poland, France, Romania, Italy, Mexico
GlaxoSmithKline

Completed

QTc Study GSK573719+GW642444

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Argentina, Australia, United States, Germany, Chile, Korea, Republic of, Mexico, Canada, South Africa, Romania
GlaxoSmithKline

Completed

A Study of GSK573719 in Healthy Japanese Male Subjects

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

28-day Repeat Dose Study of GSK573719

Pulmonary Disease, Chronic Obstructive

United States, Estonia, Germany, Poland
GlaxoSmithKline

Completed

A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Taiwan, Thailand, China, Philippines, Korea, Republic of
Gary L. Pierce

Completed

Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients

COPD

United States
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (COPD)

Pulmonary Disease, Chronic Obstructive

South Africa, United States, Canada, Ukraine, United Kingdom, Denmark, Czechia
GlaxoSmithKline

Completed

A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719 in Japanese (AC4115361)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

GSK573719 IV Enabling Study

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719/GW642444 in Japanese (DB2115362)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (COPD nDPI)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Slovakia
Luis Puente Maestu

Recruiting

Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure (CHHEF)

Heart Failure | Copd

Spain
GlaxoSmithKline

Completed

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Germany, Japan, United States
GlaxoSmithKline

Completed

A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719

Pulmonary Disease, Chronic Obstructive

Netherlands
GlaxoSmithKline

Completed

A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Ukraine, Slovakia
GlaxoSmithKline

Completed

Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, United States, South Africa
Orion Corporation, Orion Pharma

Completed

Inspiratory Flow Parameters and Handling of Easyhaler and Turbuhaler Inhalers (PIFECO)

Pulmonary Disease, Chronic Obstructive | Asthma

United Kingdom, Finland
GlaxoSmithKline

Completed

Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg

Pulmonary Disease, Chronic Obstructive

Germany, Estonia
Synspira, Inc.

Terminated

A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis

Lung Diseases | Cystic Fibrosis | Pulmonary Disease | Antibiotic Resistant Infection | Respiratory Tract Disease | Cystic Fibrosis Pulmonary Exacerbation | Lung Inflammation | Burkholderia Infections | Lung Infection | Multi-antibiotic Resistance | Pulmonary Inflammation | Lung Infection Pseudomonal | Cystic Fibrosis... and other conditions

United Kingdom
GlaxoSmithKline

Withdrawn

Aura Adolescent PK Study GSK2829332

Asthma
GlaxoSmithKline

Completed

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects (DB2113208)

Pulmonary Disease, Chronic Obstructive

Australia
Galecto Biotech AB

Completed

RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients

Idiopathic Pulmonary Fibrosis

United Kingdom
Makerere University
University of Copenhagen

Completed

Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial (ICS)

Bacterial Pneumonia | Acute Asthma | Viral Pneumonia

Uganda
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.

Cough

United Kingdom
Boehringer Ingelheim

Completed

The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.

Pulmonary Disease, Chronic Obstructive

Spain
Pearl Therapeutics, Inc.

Completed

Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers

Healthy Volunteers

United States
Liquidia Technologies, Inc.
Nuventra, Inc.

Completed

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil (INSPIRE)

Primary Pulmonary Hypertension

United States
GlaxoSmithKline

Completed

A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function

Asthma

New Zealand
National Heart, Lung, and Blood Institute (NHLBI)
Childhood Asthma Research and Education Network

Completed

Prevention of Early Asthma in Kids (PEAK)

Lung Diseases | Asthma
Liquidia Technologies, Inc.
Nuventra, Inc.

Active, not recruiting

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

Primary Pulmonary Hypertension

United States
Alexza Pharmaceuticals, Inc.

Completed

Staccato Prochlorperazine in Migraine (Out Patient)

Migraine Headache | Aura

United States
Ajou University School of Medicine
AstraZeneca

Recruiting

Long-term Effect of Steroid on Metabolic Diseases in Asthmatics

Asthma | Osteoporosis Risk | Osteoporotic Fractures | Osteoporosis, Osteopenia

Korea, Republic of
GlaxoSmithKline

Completed

WEUKBRE5554: IMI PROTECT(Work Package 2): Beta2 Agonists and Acute Myocardial Infarction

Asthma
Massachusetts General Hospital
Rezoagli, Emanuele, M.D., Massachusetts General Hospital, Harvard Medical... and other collaborators

Active, not recruiting

Prolonged Hypoxic Breathing in Healthy Volunteers: a Safety Study (MGH-nitrogen)

Healthy Volunteers

United States
Washington University School of Medicine
Barnes-Jewish Hospital

Completed

Controlled Clinical Trial of Supplemental Oxygen for the Prevention of Post-Cesarean Infectious Morbidity (Peri-Op)

Surgical Wound Infection | Endometritis | Infection; Cesarean Section

United States
Aridis Pharmaceuticals, Inc.

Recruiting

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

Cystic Fibrosis

United States
Imperial College London

Completed

Measuring Hydrogen Peroxide in Exhaled Breath Condensate in HV

Proof Of Concept Study

United Kingdom
GlaxoSmithKline

Completed

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Asthma

United States, Argentina, Germany, Korea, Republic of, Romania, Russian Federation, Spain, Netherlands, Mexico, Brazil, Chile, Czechia
Liquidia Technologies, Inc.
FGK Clinical Research GmbH

Terminated

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

Pulmonary Arterial Hypertension

France, Germany
ISBRG Corp
National Advanced Driving Simulator

Recruiting

Detection of Cannabis Impairment With ISBRG's SpotLight-THC

Cannabis

United States
Novartis

Completed

A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma

Bronchial Asthma

Germany

3

Subscribe